Skip to main content

Table 4 Incidence of adverse events in the two study groups from inclusion to day 7 of follow up

From: Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial

  Day 1 Day 2 Day 3 Day 7
Adverse event AM AL AM AL AM AL AM MF
Dizziness (n,%) 35 (22.3) 17 (11.1) 61 (38.8) 8 (5.2) 58 (38.1) 11 (7.1) 15 (10.2) 6 (4.03)
Vomit (n,%) 16 (10.2) 11 (7.2) 09 (5.7) 0 04 (2.6) 0 0 0
Abdominal pain 15 (9.5) 11 (7.2) 11 (7.2) 10 (6.5) 10 (6.5) 4 (2.6) 1 (0.66) 0
Pruritus (n,%) 0 2 (1.3) 0 1 (0.6) 0 0 0 0
Oral herpes (n,%) 0 2 (1.3) 0 3 (1.9) 1 (0.66) 3 (1.9) 0 1 (0.67)
  1. AM = Artesunate-mefloquine; AL = Artemether-Lumefantrine.